Table 2. Patient characteristics.

Patient	Cancer	Metastasis site	Age	TNM 1	Stage 2
1	SCLC	none	56	Extended disease3	–
2	SCLC	liver	79	Extended disease3	–
3	SCLC	adrenal gland	52	Extended disease3	–
4	SCLC	bone	64	Extended disease3	–
5	NSCLC	none	84	T1N0M0	I
6	NSCLC	none	69	pT1N0M0	I
7	NSCLC	none	78	pT1N0M0	I
8	NSCLC	bone	52	T1N0M1	IV
9	NSCLC	none	74	pT2N0M0	I
10	NSCLC	none	50	T2N0M0	I
11	NSCLC	none	76	T2N0M0	I
12	NSCLC	none	56	pT2N0M0	I
13	NSCLC	none	66	pT2N1M0	II
14	NSCLC	none	62	T2N2M0	IIIA
15	NSCLC	none	72	T2N2M0	IIIA
16	NSCLC	none	58	T2N3M0	IIIB
17	NSCLC	adrenal gland	63	T2N0M1	IV
18	NSCLC	bone	70	T2N0M1	IV
19	NSCLC	bone	57	T2N2M1	IV
20	NSCLC	adrenal gland, bone	50	T2N2M1	IV
21	NSCLC	bone	61	T2N2M1	IV
22	NSCLC	bone, liver	50	T2N3M1	IV
23	NSCLC	adrenal gland	71	T2N3M1	IV
24	NSCLC	bone	57	T2N3M1	IV
25	NSCLC	none	53	T3NXM0	IIIA-B
26	NSCLC	none	56	T3N2M0	IIIA
27	NSCLC	none	81	pT3N2M0	IIIA
28	NSCLC	lung	76	T3N2M1	IV
29	NSCLC	bone	71	T3N2M1	IV
30	NSCLC	bone	66	T3N3M1	IV
31	NSCLC	adrenal gland, brain	54	T3N3M1	IV
32	NSCLC	none	75	T4N0M0	IIIB
33	NSCLC	brain, bone	59	T4N3M1	IV
34	NSCLC	surrenal	45	T4N3M1	IV
35	NSCLC	bone	77	T4N3M1	IV
36	NSCLC	liver	77	T4N3M1	IV
37	NSCLC	brain	63	T4N3M1	IV
38	prostate	bone	62	T3N0M1	IV
39	prostate	bone	84	pT3bN1M1	IV
40	prostate	bladder	71	T3N2M1	IV
41	prostate	bone	64	T3N2M1	IV
42	prostate	none	68	T4N0M0	IIIB
43	prostate	bone	66	T4N0M1	IV
44	prostate	bone	64	T4N0M1	IV
45	colon	bone	59	pT3N1M1	IV
46	colon	bone	66	pT4N0M1	IV
47	bladder	bone	86	pT3NXM1	IV
48	bladder	bone	75	pT3bN2M1	IV
49	pancreas	multiple	36	T4N2M1	IV
50	kidney	bone	74	pT1aN0M1	IV

¹TNM interantional classification: T(primary tumor), N(primary regional lymphonodes), M (metastasis), p (post-surgery)

²tumor hystologic grading

³Veterans Administration Lung Cancer Study Group (VALCSG)